SG11201803703UA - Anti-complement factor c1q fab fragments and uses thereof - Google Patents

Anti-complement factor c1q fab fragments and uses thereof

Info

Publication number
SG11201803703UA
SG11201803703UA SG11201803703UA SG11201803703UA SG11201803703UA SG 11201803703U A SG11201803703U A SG 11201803703UA SG 11201803703U A SG11201803703U A SG 11201803703UA SG 11201803703U A SG11201803703U A SG 11201803703UA SG 11201803703U A SG11201803703U A SG 11201803703UA
Authority
SG
Singapore
Prior art keywords
international
pct
fab fragments
seaport
november
Prior art date
Application number
SG11201803703UA
Inventor
Ted Yednock
Sethu Sankaranarayanan
Arnon Rosenthal
Michael Leviten
Original Assignee
Annexon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Annexon Inc filed Critical Annexon Inc
Publication of SG11201803703UA publication Critical patent/SG11201803703UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property , Organization 11 M1111101110101011111 HO 11111 0101101H HO 1101111101111101111011 1111 International Bureau r..... .Yi j (10) International Publication Number (43) International Publication Date ..... ...r .....1 WO 2017/091719 Al 1 June 2017 (01.06.2017) WIPO I PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07K 16/18 (2006.01) C12N 15/13 (2006.01) A61K 39/395 (2006.01) A61P 25/28 (2006.01) G01N 33/53 (2006.01) A61P 25/00 (2006.01) G01N 33/534 (2006.01) A61P 27/02 (2006.01) A61K 49/16 (2006.01) A61P 37/00 (2006.01) kind AO, BZ, DO, HN, KW, of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (21) International Application Number: PCT/US2016/063587 MG, OM, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (22) International Filing Date: 23 November 2016 (23.11.2016) SC, TN, ZW. SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: 62/259,227 24 November 2015 (24.11.2015) US GM, TZ, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: ANNEXON, INC. [US/US]; 280 Utah Street, Suite 110, South San Francisco, CA 94083-6883 (US). DK, LV, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, _ (72) Inventors: YEDNOCK, Ted; 184 Arroyo Road, Forest Knolls, CA 94333 (US). SANKARANARAYANAN, SM, GW, KM, ML, MR, NE, SN, TD, TG). TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Sethu; 4720 Falstaff Avenue, Fremont, CA 94555 (US). Published: ROSENTHAL, Arnon; 150 Normandy Lane, Woodside, CA 94062 (US). LEVITEN, Michael; 502 Live Oak Lane, Emerald Hills, CA 94062 (US). with international search report (Art. 21(3)) = (74) Agents: HALSTEAD, David P. et al.; Foley Hoag LLP, Seaport West, 155 Seaport Boulevard, Boston, MA 02210- = _ 2600 (US). = = = = = = = = = = = Il C:r 11 IN 11 C:r © IN 11 © N C (54) Title: ANTI-COMPLEMENT FACTOR C1Q FAB FRAGMENTS AND USES THEREOF (57) : The present disclosure relates generally to anti-Clq antibody Fab fragments and methods of using the same.
SG11201803703UA 2015-11-24 2016-11-23 Anti-complement factor c1q fab fragments and uses thereof SG11201803703UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562259227P 2015-11-24 2015-11-24
PCT/US2016/063587 WO2017091719A1 (en) 2015-11-24 2016-11-23 Anti-complement factor c1q fab fragments and uses thereof

Publications (1)

Publication Number Publication Date
SG11201803703UA true SG11201803703UA (en) 2018-06-28

Family

ID=58763681

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201803703UA SG11201803703UA (en) 2015-11-24 2016-11-23 Anti-complement factor c1q fab fragments and uses thereof

Country Status (11)

Country Link
US (2) US10723788B2 (en)
EP (1) EP3380518A4 (en)
JP (1) JP6976943B2 (en)
KR (1) KR20180093955A (en)
CN (2) CN108779171B (en)
AU (1) AU2016361517B2 (en)
BR (1) BR112018010360A2 (en)
CA (1) CA3006092A1 (en)
IL (2) IL296130A (en)
SG (1) SG11201803703UA (en)
WO (1) WO2017091719A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6774164B2 (en) 2012-08-24 2020-10-21 中外製薬株式会社 Mouse FcγRII specific Fc antibody
WO2014163101A1 (en) 2013-04-02 2014-10-09 中外製薬株式会社 Fc region variant
EP3019240B1 (en) 2013-07-09 2024-03-13 Annexon, Inc. Anti-complement factor c1q antibodies and uses thereof
KR102626877B1 (en) 2014-11-05 2024-01-19 애넥슨, 인코포레이티드 Humanized Anti-Complement Factor C1Q Antibodies and Uses Thereof
AU2016361517B2 (en) 2015-11-24 2023-12-14 Annexon, Inc. Anti-complement factor C1q Fab fragments and uses thereof
CN112313249A (en) * 2018-04-13 2021-02-02 中外制药株式会社 Anti-complement component antibodies and methods of use
MX2021006864A (en) 2018-12-13 2021-07-02 Argenx Bvba Antibodies to human complement factor c2b and methods of use.
GB2584105B (en) * 2019-05-21 2023-08-02 Argenx Bvba Methods of treating neuropathy
US20240109957A1 (en) * 2019-10-17 2024-04-04 Annexon, Inc. Compositions and methods for treating blood disorders
CN110716038B (en) * 2019-10-23 2022-08-30 俞梦越 Acute coronary syndrome complement detection kit and use method thereof
CN112194719A (en) * 2020-09-01 2021-01-08 中日友好医院(中日友好临床医学研究所) Preparation and application of CRT antigen and MAGE-A1 antigen
CN112837822B (en) * 2020-09-24 2023-05-02 广州市疾病预防控制中心(广州市卫生检验中心、广州市食品安全风险监测与评估中心、广州医科大学公共卫生研究院) Marker for predicting light-to-heavy progress of patient with COVID-19, kit and establishment method
AU2021361067A1 (en) * 2020-10-16 2023-06-01 Annexon, Inc. Compositions and methods for treating blood disorders
CA3200976A1 (en) * 2020-12-04 2022-06-09 Anita GROVER Compositions and methods for treating ocular diseases
WO2023130001A1 (en) * 2021-12-30 2023-07-06 Annexon, Inc. Compositions and methods for treating huntington's disease
WO2023212719A1 (en) * 2022-04-29 2023-11-02 Annexon, Inc. Compositions and methods for treating ocular diseases
WO2023220750A1 (en) * 2022-05-13 2023-11-16 Annexon, Inc. Compositions and methods for treating lupus nephritis

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4595654A (en) 1983-11-07 1986-06-17 Immunomedics Inc. Method for detecting immune complexes in serum
US6717031B2 (en) 1995-06-07 2004-04-06 Kate Dora Games Method for selecting a transgenic mouse model of alzheimer's disease
US20020058311A1 (en) 1995-06-13 2002-05-16 Browne Michael Jospeh Chimeric leptin fused to immunoglobulin domain and use
DE69729209T2 (en) 1996-11-27 2005-05-19 Genentech, Inc., South San Francisco HUMANIZED ANTI-KOERPER AGAINST CD11A
US20050197285A1 (en) 1997-03-07 2005-09-08 Rosen Craig A. Human secreted proteins
EP1009829B1 (en) 1997-08-26 2006-04-26 ZymoGenetics, Inc. Adipocyte-specific protein homologs
US20030170781A1 (en) 1999-07-01 2003-09-11 Zymogenetics, Inc. Secreted protein zacrp4
AU2001278919A1 (en) 2000-07-13 2002-01-30 University Of South Florida Transgenic animal and methods
US6872559B2 (en) 2000-10-26 2005-03-29 Wisconsin Alumni Research Foundation E. coli O157:H7 C1 esterase inhibitor-binding protein and methods of use
BR0207267A (en) 2001-02-19 2004-02-10 Merck Patent Gmbh Artificial proteins with reduced immunogenicity
WO2003052377A2 (en) 2001-11-07 2003-06-26 Human Genome Sciences, Inc. 41 human secreted proteins
US20040248156A1 (en) 2001-12-03 2004-12-09 Tianhua Hu Methods and materials relating to novel C1q domain-containing polypeptides and polynucleotides
US20050214786A1 (en) 2002-02-22 2005-09-29 Human Genome Sciences, Inc. 26 human secreted proteins
AU2004241069B2 (en) 2003-05-15 2010-09-09 Genentech, Inc. Methods and compositions for the prevention and treatment of sepsis
US20050019326A1 (en) 2003-06-16 2005-01-27 The Brigham And Women's Hospital, Inc. C1q complement inhibitors and methods of use thereof
WO2005002512A2 (en) 2003-06-19 2005-01-13 University Of Rochester Immunotherapeutic vaccine strategy
US8501705B2 (en) 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
US7544855B2 (en) 2004-04-23 2009-06-09 Buck Institute Transgenic mouse whose genome comprises an APP having a mutation at amino acid 664
EP1819731A4 (en) 2004-12-08 2013-02-13 Immunomedics Inc Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
JP4753683B2 (en) 2005-10-14 2011-08-24 オルテック インコーポレイテッド Methods and compositions for altering cell function
US9480658B2 (en) * 2005-12-09 2016-11-01 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
US8148330B2 (en) 2005-12-09 2012-04-03 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
KR101413615B1 (en) 2006-03-23 2014-07-18 바이오악틱 뉴로사이언스 에이비 Improved antibody selective for human protofibrils and the use thereof
US7919079B2 (en) * 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
PL2061810T3 (en) 2006-09-05 2015-05-29 Alexion Pharma Inc Methods and compositions for the treatment of antibody mediated neuropathies
WO2012067267A1 (en) 2010-11-18 2012-05-24 Takahiro Ochi TESTING METHOD USING ANTI-C1q MONOCLONAL ANTIBODY
JPWO2012176765A1 (en) 2011-06-24 2015-02-23 株式会社ペルセウスプロテオミクス Anti-human P-cadherin (CDH3) gene recombinant antibody
RS61755B1 (en) 2012-06-18 2021-05-31 Omeros Corp Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders
WO2014066744A2 (en) 2012-10-25 2014-05-01 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
RS63212B1 (en) 2012-11-02 2022-06-30 Bioverativ Usa Inc Anti-complement c1s antibodies and uses thereof
WO2014161570A1 (en) 2013-04-03 2014-10-09 Roche Glycart Ag Antibodies against human il17 and uses thereof
US20160053023A1 (en) 2013-04-09 2016-02-25 Annexon, Inc. Methods of treatment for neuromyelitis optica
WO2014186599A2 (en) 2013-05-15 2014-11-20 Annexon, Inc. Anti-complement factor c1s antibodies and uses thereof
EP3019240B1 (en) * 2013-07-09 2024-03-13 Annexon, Inc. Anti-complement factor c1q antibodies and uses thereof
KR102626877B1 (en) * 2014-11-05 2024-01-19 애넥슨, 인코포레이티드 Humanized Anti-Complement Factor C1Q Antibodies and Uses Thereof
AU2016361517B2 (en) 2015-11-24 2023-12-14 Annexon, Inc. Anti-complement factor C1q Fab fragments and uses thereof
KR20190005944A (en) * 2016-05-09 2019-01-16 애넥슨, 인코포레이티드 COMPOSITION AND METHOD FOR THE TREATMENT OF SPINAL MUSCLE
EP3487531A4 (en) * 2016-07-19 2020-03-25 Annexon, Inc. Compositions and methods for treating frontotemporal dementia

Also Published As

Publication number Publication date
BR112018010360A2 (en) 2018-12-04
AU2016361517A1 (en) 2018-06-14
NZ742877A (en) 2023-11-24
US10723788B2 (en) 2020-07-28
CN108779171A (en) 2018-11-09
US20170152309A1 (en) 2017-06-01
CA3006092A1 (en) 2017-06-01
EP3380518A4 (en) 2019-07-31
IL296130A (en) 2022-11-01
CN115260310A (en) 2022-11-01
WO2017091719A1 (en) 2017-06-01
JP2019501132A (en) 2019-01-17
JP6976943B2 (en) 2021-12-08
AU2016361517B2 (en) 2023-12-14
IL259079B2 (en) 2023-02-01
EP3380518A1 (en) 2018-10-03
IL259079A (en) 2018-06-28
US20200317765A1 (en) 2020-10-08
IL259079B (en) 2022-10-01
CN108779171B (en) 2022-07-05
KR20180093955A (en) 2018-08-22

Similar Documents

Publication Publication Date Title
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201905699XA (en) Anti-icos agonist antibodies and uses thereof
SG11201811184UA (en) Lag -3 binding members
SG11201901126UA (en) Combination therapy for cancer
SG11201809857TA (en) Anti-CTLA-4 Antibodies
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201810509PA (en) Anti-pd-l1 antibodies
SG11201900772YA (en) Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201807401RA (en) Therapeutic membrane vesicles
SG11201810034XA (en) ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
SG11201807279QA (en) Binding proteins and methods of use thereof
SG11201903835WA (en) Antibodies directed against programmed death- 1 (pd-1)
SG11201808913WA (en) Intratumoral administration of particles containing a toll-like receptor 9 agonist and a tumor antigen for treating cancer
SG11201901020RA (en) Anti-siglec-7 antibodies for the treatment of cancer
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201408780XA (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
SG11201903771XA (en) Binding molecules specific for asct2 and uses thereof
SG11201810887UA (en) Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof
SG11201901597UA (en) Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof
SG11201806121PA (en) Ror2 antibody compositions and related methods
SG11201903785TA (en) Bivalent antibodies masked by coiled coils
SG11201900123TA (en) Compositions and methods for treating frontotemporal dementia